Annual Report for the financial year 2024-25.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd, a small pharmaceutical trading company listed on BSE (Scrip: 530207), has submitted its 40th Annual Report for FY 2024-25. The 40th Annual General Meeting will be held on 30th September 2025 at 11:00 AM via video conferencing. The register of members will be closed from 24th September to 30th September 2025. Key financial numbers show continued weakness — revenue from operations fell to Rs. 134.65 lakh from Rs. 164.95 lakh in FY24, while net loss widened to Rs. 174.01 lakh from Rs. 124.70 lakh, with EPS at Rs. (5.68). No dividend has been recommended due to the losses. Shareholders will vote on (a) re-appointment of Mrs. Brij Bala Gupta as Director retiring by rotation, (b) re-appointment of Mr. Amit Kumar as Manager (KMP) for 5 years from February 2026, and (c) adoption of a new Memorandum of Association under the Companies Act, 2013. E-voting via CDSL runs from 27th to 29th September 2025 with a cut-off date of 15th September 2025.
Negative — the company is loss-making for a second consecutive year with a widening loss and declining revenue, and shareholders get no dividend. The KMP re-appointment and MOA overhaul are routine governance items and unlikely to move the stock, though the persistent losses raise going-concern concerns worth tracking.